ada , dm , clinical Recommendations. Flashcards

(31 cards)

1
Q

What are some weight-related comorbidities that people with diabetes may have?

A

NAFLD, HF with preserved ejection fraction, obstructive sleep apnea

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What are the potential risks for people with type 2 diabetes and NAFLD?

A

Progression to more severe stages of liver disease, including NASH, hepatic fibrosis, and cirrhosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What are some recommended strategies for managing type 2 diabetes in people with NASH?

A

Lifestyle modification with a goal of weight loss, medical and/or surgical approaches to weight loss

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What are some recommended strategies for managing type 2 diabetes in people with NASH?

A

Lifestyle modification with a goal of weight loss, medical and/or surgical approaches to weight loss

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What are some recommended strategies for managing type 2 diabetes in people with NASH?

A

Lifestyle modification with a goal of weight loss, medical and/or surgical approaches to weight loss

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Which therapies have been shown to reduce NASH activity?

A

Pioglitazone therapy, GLP-1 RA therapy, metabolic surgery

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What is the suggested treatment for people with type 2 diabetes at intermediate to high risk of fibrosis?

A

Pioglitazone and/or a GLP-1 RA with evidence of benefit

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

How can SGLT2i therapy benefit people with NAFLD?

A

Reducing elevated levels of liver enzymes and hepatic fat content

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

How can SGLT2i therapy benefit people with NAFLD?

A

Reducing elevated levels of liver enzymes and hepatic fat content

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

How can SGLT2i therapy benefit people with NAFLD?

A

Reducing elevated levels of liver enzymes and hepatic fat content

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What should be assessed and managed in people with NAFLD to minimize cardiovascular risk?

A

Cardiovascular risk factors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

How have SGLT2i drugs been shown to benefit people with obstructive sleep apnea?

A

Reducing incident obstructive sleep apnea

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What are the consensus recommendations for people with type 2 diabetes?

A

Access to ongoing DSMES programs, person-centered care, optimizing medication adherence, MNT, physical activity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What are the consensus recommendations for people with type 2 diabetes?

A

Access to ongoing DSMES programs, person-centered care, optimizing medication adherence, MNT, physical activity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What are the consensus recommendations for people with type 2 diabetes?

A

Access to ongoing DSMES programs, person-centered care, optimizing medication adherence, MNT, physical activity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What is the recommended duration of physical activity for adults with type 2 diabetes?

A

> 150 min/week of moderate- to vigorous-intensity aerobic activity

17
Q

What types of training should be supplemented with aerobic activity for adults with type 2 diabetes?

A

Resistance, flexibility, and/or balance training

18
Q

When should metabolic surgery be considered as a treatment option for type 2 diabetes?

A

BMI ≥40.0 kg/m2 (BMI ≥37.5 kg/m2 in people of Asian ancestry) or a BMI of 35.0–39.9 kg/m2 (32.5–37.4 kg/m2 in people of Asian ancestry) who do not achieve durable weight loss and improvement in comorbidities

19
Q

When should metabolic surgery be considered as a treatment option for type 2 diabetes?

A

BMI ≥40.0 kg/m2 (BMI ≥37.5 kg/m2 in people of Asian ancestry) or a BMI of 35.0–39.9 kg/m2 (32.5–37.4 kg/m2 in people of Asian ancestry) who do not achieve durable weight loss and improvement in comorbidities

20
Q

When should metabolic surgery be considered as a treatment option for type 2 diabetes?

A

BMI ≥40.0 kg/m2 (BMI ≥37.5 kg/m2 in people of Asian ancestry) or a BMI of 35.0–39.9 kg/m2 (32.5–37.4 kg/m2 in people of Asian ancestry) who do not achieve durable weight loss and improvement in comorbidities

21
Q

What medications should be used in people with established CVD to reduce MACE?

A

GLP-1 RA or SGLT2i with proven benefit

22
Q

What medication should be initiated in people with CKD and an eGFR ≥20 ml/min per 1.73 m2 and a UACR >3.0 mg/mmol (>30 mg/g)?

A

SGLT2i with proven benefit

23
Q

What medication should be used in people with HF to improve HF and kidney outcomes?

24
Q

What medication should be used in people with HF to improve HF and kidney outcomes?

25
What medication could be used in individuals without established CVD but with multiple cardiovascular risk factors?
GLP-1 RA or SGLT2i with proven benefit
26
What medication could be used in individuals without established CVD but with multiple cardiovascular risk factors?
GLP-1 RA or SGLT2i with proven benefit
27
What medication could be used in individuals without established CVD but with multiple cardiovascular risk factors?
GLP-1 RA or SGLT2i with proven benefit
28
Should the decision to use a GLP-1 RA or SGLT2i be dependent on baseline HbA1c?
No, it should be independent of baseline HbA1c
29
Should medication selection for improving cardiovascular and kidney outcomes differ for older people?
No, it should not differ
30
What is the recommended approach for younger people with diabetes (<40 years)?
Consider early combination therapy
31
What counseling is important for women with reproductive potential?
Contraception and avoiding exposure to medications that may adversely affect a fetus